Full-Life Technologies Limited is a fully integrated global radiotherapeutics company headquartered in Shanghai, China with operations in Europe.
Total raised: $274.3M
Funding Rounds 3
| Date | Series | Amount | Investors |
| 19.05.2026 | Series D | $150M | Sky9 Capit... |
| 30.09.2025 | Series C | $77M | - |
| 04.01.2024 | Series B | $47.3M | - |
Mentions in press and media 23
| Date | Title | Description |
| 09.09.2026 | Full-Life Technologies Announces U.S. FDA IND Clearance and Australian Regulatory Clearance for [²²⁵Ac]Ac-FL-261 Phase 1 Clinical Trial | LONDON, Sept. 9, 2026 /PRNewswire/ -- Full-Life Technologies ("Full-Life", the "Company"), a privately held, fully integrated, clinical-stage actinium-based global radiopharmaceutical company, today announced that the U.... |
| 19.05.2026 | Full-Life Technologies: $150 Million Financing To Advance Clinical-Stage Radiotherapeutics Pipeline And Manufacturing Capabilities | Full-Life Technologies announced the completion of a US$150 million financing package comprised of approximately US$110 million in Series D equity financing and US$40 million in debt financing. The financing round was led by Vivo Capital an... |
| 30.09.2025 | Full-Life Technologies Announces US$77 Million Financing to Accelerate Development of its Radiopharmaceutical Pipeline and Manufacturing Capabilities | Series C led by Junson Capital along with new investor syndicate and existing shareholders Funding will further advance Full-Life's global radiopharmaceutical pipeline and manufacturing capabilities in Belgium Additional debt financing prov... |
| 30.09.2025 | Full-Life Technologies Raises US$77M in Financing | Full-Life Technologies, a Shangai, China-based fully-integrated global radiotherapeutics company, raised USE$77M in funding. x Please enable JavaScript Video Player is loading.Play Video Play Unmute 1xPlayback Rate 2x1.5x1x, selected0.5x Ca... |
| 06.08.2024 | Latest Updates of Viva Biotech's Portfolio Companies | HONG KONG, Aug. 6, 2024 /PRNewswire/ -- Even with the ever-changing situation, technological innovation is still the most critical component for biopharmaceutical companies' long-term development. This continuous innovation keeps companies ... |
| 17.07.2024 | Full-Life Technologies, SK Biopharmaceuticals Enter Licensing Agreement for Novel Therapeutic Targeting Multiple Solid Tumors | Full-Life Technologies seals $571.5 million agreement with SK Biopharmaceuticals to license and further develop Full-Life's 'FL-091' radiopharmaceutical compound into an innovative anti-cancer treatment for worldwide markets HEIDELBERG, Ger... |
| 16.07.2024 | Full-Life Technologies, SK Biopharmaceuticals Enter Licensing Agreement for Novel Therapeutic Targeting Multiple Solid Tumors | Full-Life Technologies seals $571.5 million agreement with SK Biopharmaceuticals to license and further develop Full-Life's 'FL-091' radiopharmaceutical compound into an innovative anti-cancer treatment for worldwide markets HEIDELBERG, Ger... |
| 02.07.2024 | Full-Life Technologies Granted FDA Fast Track Designation for 225Ac-FL-020 for the Treatment of Metastatic Castration-Resistant Prostate Cancer | HEIDELBERG, Germany, July 2, 2024 /PRNewswire/ -- Full-Life Technologies (Full-Life), a fully integrated global radiotherapeutics company, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation f... |
| 11.06.2024 | Full-Life Technologies Disclosed Preclinical Data of its NTSR1-targeting RDC Program FL-091 in an Oral Presentation at the 2024 SNMMI Annual Meeting | SHANGHAI and HEIDELBERG, Germany, June 11, 2024 /PRNewswire/ -- Full-Life Technologies (Full-Life), a fully integrated global radiotherapeutics company, released preclinical data of its NTSR1-targeting RDC program FL-091 in an oral presenta... |
| 10.06.2024 | Full-Life Technologies Disclosed Preclinical Data of its NTSR1-targeting RDC Program FL-091 in an Oral Presentation at the 2024 SNMMI Annual Meeting | SHANGHAI and HEIDELBERG, Germany, June 10, 2024 /PRNewswire/ -- Full-Life Technologies (Full-Life), a fully integrated global radiotherapeutics company, released preclinical data of its NTSR1-targeting RDC program FL-091 in an oral presenta... |
Show more